tbuckley/cabot-search huggingface dataset:
ANTITOXIN.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Conference on Cancer of the Colon and Rectum
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Conference on Cancer of the Colon and Rectum Get access JNCI: Journal of the National Cancer Institute, Volume 50, Issue 1, January 1973, Page 297, https://doi.org/10.1093/jnci/50.1.297 Published: 01 January 1973
Handbook of Tuberculosis Schemes for Great Britain and Ireland. Seventh edition.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Delayed thrombocytopenic purpura after diminutive gold therapy
Authors: J. R. Saphir
Journal: JAMA (1966)

OF THE VARIOUS forms of gold toxicity, thrombocytopenia is among the most dreaded. Occasionally, small amounts of gold have been found to produce purpura, or this manifestation could be delayed many weeks or months from time of injection.<sup>1</sup>It thus seems appropriate to report the case of the patient who developed thrombocytopenia seven months after having received a total gold dose of 50 mg. (For uniformity, all dosages of gold salts reported in this paper are in terms of metallic, or elemental, gold.) <h3>Report of a Case</h3> A 57-year-old white bus driver was admitted to the Buffalo General Hospital on Dec 29, 1964, with severe epistaxis. He had been well until two years previously, when his extremities became painful and swollen. Ten months prior to admission, four 12.5-mg gold doses (in the form of 25 mg gold sodium thiomalate) were administered at 14-day intervals, for a total of 50
Abstract 9: Cardiac BIN1 Improves Dyad Organization and Calcium Transient in Cardiomyocytes
Authors: Ying Fu, Kang Zhou, Yan Liu, Sosse Agvanian, Bing Xu, Robin M Shaw, TingTing Hong
Journal: Circulation Research (2017)

BIN1 (bridging integrator 1) is a membrane scaffolding protein that forms microfolds at t-tubules and organizes dyad microdomains essential for a normal calcium transient. Reduction of cBIN1 has emerged as a new hallmark in heart failure and is associated with impaired calcium transient and increased risk of arrhythmias. We hypothesized that gene transfer of cardiac BIN1 (cBIN1) in vivo can improve calcium transients in disease models. We introduced V5-tagged cBIN1 or GFP through AAV9-mediated expression in adult mice. Confocal imaging of isolated cardiomyocytes was used to assess organization of dyad microdomain. Calcium transients in response to acute administration of isoproterenol (ISO) was measured as functional readout of excitation-contraction (EC) coupling. Here we report that cBIN1 significantly enhanced both basal and ISO-induced increase in calcium transient compared to cells expressing GFP. Immunofluorescent labeling revealed that cBIN1 expression increased both LTCC and RyR at t-tubule. In addition, in a mouse model of ischemic cardiomyopathy, permanent LAD ligation resulted in a marked reduction in ISO-induced increment in calcium transient, indicating blunted beta-adrenergic responsiveness and impaired regulation of EC coupling machinery. In comparison, an ISO-induced increment in calcium transient was largely maintained in cBIN1-expressing cells. These results demonstrate that cBIN1 increases calcium transients by upregulating and organizing dyad proteins at t-tubule microfolds. More importantly, cBIN1 rescues diminished beta-adrenergic responsiveness in ischemic cardiomyopathy and improves EC coupling of viable cardiomyocytes. This work suggests that cBIN1 provides a therapeutic opportunity to improve cardiac function in ischemic cardiomyopathy and heart failure.
Everyday Nursing for the Everyday Home
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bone banks.
Authors: J. N. Kearney
Journal: BMJ (1992)

time to take effect.Our patients described their recovery in terms of a "cracked mirror" 10-15 minutes after the injection.Angiography was performed 60 minutes after injection and showed complete reopening.With regard to the adverse side effects mentioned by Pandit and Tiamiyu, cardiac arrhythmias were reported after longer administra- tion of higher doses of steroids (4x 30 mg/kg daily),' not after a single 1000 mg bolus, which is not a massive dose.Steroids are an effective measure against anaphylactic shock.4Are anaphy- lactoid reactions to steroids really common?We tried to show the effect of steroids on vessel walls and offered angiographic evidence that occluded vessels became completely perfused 60 minutes later.A steroid bolus seems to us to be a suitable emergency treatment that does not inter- fere with other drugs for this condition.Any other treatment may be given simultaneously or after- wards.
Abstract 19473: Safety and Efficacy of Second Generation Self Expanding Portico® Valve System for the Treatment of Failed Aortic Bioprosthesis: Results From an International Multicenter Valve-in-Valve Registry
Authors: Sami Alnasser, Danny Dvir, Thomas Walther, Won-Keun Kim, Franscesco Bedogni, Luca Testa, Hafid Amrane, Ad van Boven, Han Blomer, Marc Pelletier, Josep Rodes-Cabau, Maria Del Trigo, Nicolas van Mieghem,, Peter de Jaegere, Christian Frerker, Ganesh Manoharan, Mark Spence, Stephen Worthley, Anita Asgar, Reda Ibrahim Reda Ibrahim, Carmelo Sgroi Carmelo Sgroi, Gerlando Pilato Gerlando Pilato, Dion Stub, John Webb, Asim Cheema
Journal: Circulation (2015)

Background: Portico valve is a second-generation self-expanding repositionable system with a nitinol stent frame and bovine pericardial leaflets, which is increasingly utilized for transcatheter aortic valve replacement (TAVR) . In this report, we describe the procedural and early clinical results from an international multicenter registry of Portico implantation in patients with degenerated aortic bioprosthesis (Portico ViV). Methodology: Baseline data and outcomes were collected on standard case report forms and by the Valve-in-Valve International Data network from 14 centers across three continents. Procedural endpoints included implantation success and coronary obstruction. Clinical endpoints included death, myocardial infarction (MI), stroke, major bleeding at 30 days as defined by Valve Academic Research consortium II (VARCII). Result: 45 patients undergoing Portico ViV were included in analysis. The mean age was 79± 7 years with STS (mortality) score of 7±4. These procedures had mainly utilized peripheral arterial access (93%), with transesophageal echocardiogram guidance (60%) for treatment of surgical valve label size ≤21, &gt;21-&lt;25, and ≥25mm in 36, 38 and 27% respectively. Four (9%) of the failed surgical bioprostheses were stentless. Successful implantation was achieved in 44 (98%) cases with no malposition events or clinically-evident coronary obstruction. Post implantation valve area was 1.3 ±0.4 cm2, mean gradient of 17.1 ± 7.7 mmHg and ≥ moderate aortic insufficiency was observed in 3 (7%). One death (2%) related to ischemic stroke occurred within 30 days. Major bleeding and vascular complication in 5 (11%) and 1 (2%) respectively. One patient required permanent pacemaker implantation (2%). Conclusion: Results from this international multicenter registry show that Portico offers a safe and effective treatment of failed surgical bioprosthesis with an added advantage of device retrievability, resulting in low incidence of malpositioning and coronary obstruction. Additional studies and comparison with other transcatheter devices should further determine the hemodynamic and clinical performance of this device for selection of optimal treatment of high risk patients with failed surgical bioprostheses
Aphasia and other Speech Defects.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Obituary
Authors: Renslow Sherer
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Noise and Stress: A Comprehensive Approach
Authors: Jack C. Westman, James R. Walters
Journal: Environmental Health Perspectives (1981)

The fundamental purposes of hearing are to alert and to warn. As a result sound directly evokes emotions and actions. The processing of sound by the brain is outlined to provide a biological and psychological basis for understanding the way in which sound can become a human stressor. The auditory orienting response, startle reflex and defensive response translate sound stimuli into action and sometimes into stress induced bodily changes through "fight or flight" neural mechanisms. The literature on the health and mental health effects of noise then is reviewed in the context of an integrated model that offers a holistic approach to noise research and public policy formulation. The thesis of this paper is that research upon, and efforts to prevent or minimize the harmful effects of noise have suffered from the lack of a full appreciation of the ways in which humans process and react to sound.
Hepatic Reticuloendothelial ???Failure??? in Schistosoma Mansoni Infestation
Authors: KOLLI SURESH, JOHN W. TURNER, RICHARD P. SPENCER, SAID M. ZU??BI
Journal: Clinical Nuclear Medicine (1977)

A 34-year-old man with Schistosoma mansoni infestation showed lack of hepatic uptake of intravenously administered 99mTc-sulfur colloid. There was a shift of radiocolloid accumulation to the spleen, but not to the bone marrow. Five years previously, the liver had shown uptake of radioactive colloid. Other disorders which are also associated with failure of the liver to accumulate radiocolloid are discussed. Hepatic imaging in such cases, by means of 131l-rose bengal and 67Ga-citrate, was mentioned.
Pathology
Authors: Cecilia M. Fenoglio
Journal: JAMA (1984)

As with any field, large numbers of developments have occurred in pathology, including a better understanding of acquired immune deficiency syndrome, the application of specific antibodies to tissue and serological diagnoses, the application of gene probes to an understanding of disease, many studies on the importance of neurotransmitters in the genesis of innumerable pathological states as well as the appreciation that neurotransmitters are present in places that were unexpected, work on viral-related lesions such as human papilloma virus-associated lesions, new studies elucidating the nature of Alzheimer's disease, and studies on lipids with respect to atherosclerosis. It is obviously impossible to cover all of these areas and, therefore, we have chosen some of the broader issues that have had an impact on numerous areas of pathology. We have also chosen to discuss Alzheimer's disease because of the new insights that are being gained in the pathogenesis of this disorder. Diagnosis and
Drug distribution following intravenous regional anesthesia
Authors: R. B. Knapp
Journal: JAMA (1967)

THE technique of intravenous regional anesthesia, similar to that produced by Bier in 1908,<sup>1</sup>has achieved considerable interest and popularity since its description by Holmes in 1963 and 1964.<sup>2,3</sup> The sudden release of 150 to 200 mg of lidocaine into the systemic circulation is a danger that was the subject of an editorial inThe Journalin 1965.<sup>4</sup>A warning was raised against the clinical use of this technique until basic studies have given answers to the following questions: (1) What is the rate of degradation (if any) of the anesthetic per unit of mass within the limb? (2) How much of the anesthetic is present intravascularly within the limb at the time of tourniquet release? This investigation has attempted to clarify some of these unknowns with lidocaine tagged with carbon 14, particularly the fate of lidocaine administered intravenously to an exsanguinated limb fitted with a tourniquet.
A novel signaling mechanism between gas and blood compartments of the lung
Authors: Wolfgang M. Kuebler, Kaushik Parthasarathi, Ping M. Wang, Jahar Bhattacharya
Journal: Journal of Clinical Investigation (2000)

Figure 7 Effects of cPLA 2 and its products.(a and b) Tracings from single experiments.Alveolar or capillary routes of TNF-α infusion are indicated.Replicated 4 times each.(c) Group data for indicated inhibitors given in 10-minute alveolar infusions before alveolar infusion of TNF-α; n = 4 for each.A P < 0.05 vs. baseline (open bar).B P < 0.05 vs. TNF-α (solid bar).COCF 3 , AACOCF 3 ; indo, indomethacin; MK, MK886; WEB, WEB 2170BS.(d) Alveoli were permeabilized by 10-minute saponin infusions.Then arachidonate was infused into permeabilized (closed circles) and control (open circle) alveoli.Each point is the mean ± SEM of 4 experiments.Line was drawn by linear regression (P < 0.001).A novel signaling mechanism between gas and blood compartments of the lung
Hodgkin lymphoma
Authors: D Maucort-Boulch, M Djeridane, P Roy, B Riche, P Colonna, J Andrieu, L Jakovic, V Bumbasirevic, M Perunicic Jovanovic, A Bogdanovic, D Boskovic, B Mihaljevic, I Biasoli, P Franchi-Rezgui, D Sibon, J Brie `re, E De Kerviler, C Thieblemont, V Levy, P Brice, K Karube, R Aoki, D Niino, Y Kimura, K Hashikawa, N Suefuji, Y Sugita, Y Nomura, K Shimizu, S Yoshida, M Takeshita, M Kikuchi, K Ohshimja
Journal: Annals of Oncology (2008)
THE DIAGNOSIS OF TYPHOID.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
British Photodermatology Group
Authors: Z Ali, A Langton, R Watson, C Griffiths, K Bedair, A Elhadad, S Hamad, J Ferguson, P Donnan, R Dawe
Journal: British Journal of Dermatology (2020)

Ultraviolet A1 (UVA1) did not start to be used in the U.K. until 1996.It is still not available in most centres, despite being especially helpful in some of the sclerosing/fibrosing and granulomatous conditions and, where available, for some individuals with commoner conditions such as atopic eczema and nodular prurigo.A concern is that it might increase the risk of skin cancer.Case reports of people who have had UVA1 therapy who have then developed cutaneous melanoma and Merkel cell carcinoma have been published.We assessed UVA1 exposure in patients who had been exposed to this treatment between 1996 and 2016.Phototherapy data were linked to cancer registry data.We estimated standardized incidence rates (SIRs) and 95% confidence intervals (CIs) by comparing them with general population data both before and after UVA1 exposure.We followed-up (i) from 1 June 1979 until first UVA1 exposure, and then (ii) from first UVA1 exposure until 31 December 2016 (or earlier 'censoring'), 297 patients who received 419 courses of UVA1.Mean age at first UVA1 treatment was 46.5 years (range 12.9-91.4years).Most (67%) were women and the majority (93%) had sunreactive skin phototypes I-III.In total, 232 had received < 50 UVA1 treatments, 61 between 51 and 350 and four had ≥ 351 cumulative whole-body UVA1 treatments.We identified six skin cancers in five separate patients.None had also received ultraviolet B phototherapy or psoralen plus ultraviolet A. The SIR for squamous cell carcinoma (SCC) was 3.75 (95% CI 0.91-10.96)after UVA1 exposure vs. 1.39 (95% CI 1.12-1.70)before UVA1.Although not a significant association after exposure, this population were at significantly increased risk before exposure.Of those who developed SCCs, one (who received a single course of 10 UVA1 treatments) was diagnosed with two SCCs simultaneously 3 years after UVA1, one was diagnosed with an SCC 6 years after first exposure to UVA1 (of which she had had a cumulative 152 treatments) and one (who had received 31 treatments) had SCC 10 years after first UVA1.There was no detectable association between UVA1 and BCC and no melanomas or Merkel cell carcinomas were identified.The numbers are still modest and follow-up was not for more than 20 years.Therefore, we cannot discount any increased risk of skin cancer in patients treated with UVA1.However, it is reassuring that, so far, no definite skin cancer risk likely attributable to UVA1 is evident.